Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s LymphomaStephen M. Ansell, David J. Straus, Radhakrishnan Ramchandren et al.|New England Journal of Medicine|2022Cited by 342
Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 StudyJoseph M. Connors, John Radford, Anas Younes et al.|Blood|2018Cited by 6
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 StudyNancy L. Bartlett, Marco Picardi, David J. Straus et al.|Blood|2019Cited by 1